Fisher Asset Management LLC Has $16.59 Million Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Fisher Asset Management LLC lowered its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 5.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,299,374 shares of the biopharmaceutical company’s stock after selling 72,188 shares during the period. Fisher Asset Management LLC’s holdings in Dynavax Technologies were worth $16,593,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. US Bancorp DE raised its holdings in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in Dynavax Technologies in the 3rd quarter worth about $45,000. GAMMA Investing LLC increased its holdings in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 1,457 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,679 shares in the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in Dynavax Technologies in the 4th quarter worth about $71,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Trading Down 1.9 %

Shares of DVAX stock opened at $13.53 on Tuesday. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of 75.17 and a beta of 1.32. The stock has a 50-day moving average of $12.91 and a 200-day moving average of $12.14. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $14.05.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. The company had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, equities research analysts forecast that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Analysts Set New Price Targets

DVAX has been the subject of a number of recent research reports. StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st. The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $31.00 price target on shares of Dynavax Technologies in a research note on Friday, February 21st.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.